IP Verse

Combination Therapy For The Treatment Of Ovarian Cancer - EP2825558

EP2825558

F HOFFMANN LA ROCHE
Application Number
EP13708435A
Filing Date
Mar 11, 2013
Status
Granted And Under Opposition
Apr 12, 2019
Grant Date
May 15, 2019
External Links
Slate, Register, Google Patents

Bibliography

The patent EP2825558B1 was granted to F Hoffmann LA Roche on May 15, 2019 following the initial filing on Mar 11, 2013 under the application number EP13708435A . The current legal status of the patent is Granted And Under Opposition.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ZENTIVA PHARMAAug 28, 2024INTERVENTION ADMISSIBLE
AMGENFeb 17, 2020WITHDRAWN
CELLTRIONFeb 17, 2020WITHDRAWN
DR REDDYS LABORATORIESFeb 17, 2020WITHDRAWN
GRUNECKER PATENT UND RECHTSANWALTE PARTG MBBFeb 17, 2020WITHDRAWN
DEHMEL & BETTENHAUSEN PATENTANWALTE PARTMBBFeb 14, 2020ADMISSIBLE
MABXIENCE RESEARCHFeb 14, 2020ADMISSIBLE
STADA ARZNEIMITTELFeb 14, 2020ADMISSIBLE
HOFFMANN EITLEFeb 14, 2020WITHDRAWN
POHLMANFeb 14, 2020WITHDRAWN

Patent Citations New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePatent NumberPatent Link
DESCRIPTIONUS20070991302-
DESCRIPTIONEP0666868
DESCRIPTIONUS2003190317
DESCRIPTIONUS2003203409
DESCRIPTIONUS2003206899
DESCRIPTIONUS2005079574
DESCRIPTIONUS2005112126
DESCRIPTIONUS2005119455
DESCRIPTIONUS2005186208
DESCRIPTIONUS2005266000
DESCRIPTIONUS2006009360
DESCRIPTIONUS2007061900
DESCRIPTIONUS2007117126
DESCRIPTIONUS2007160598
DESCRIPTIONUS2007237764
DESCRIPTIONUS2007292936
DESCRIPTIONUS2009002360
DESCRIPTIONUS3773919
DESCRIPTIONUS4816567
DESCRIPTIONUS5500362
DESCRIPTIONUS5750373
DESCRIPTIONUS5770429
DESCRIPTIONUS5821337
DESCRIPTIONUS6054297
DESCRIPTIONUS6075181
DESCRIPTIONUS6150584
DESCRIPTIONUS6582959
DESCRIPTIONUS6703020
DESCRIPTIONUS6884879
DESCRIPTIONUS6982321
DESCRIPTIONUS7041870
DESCRIPTIONUS7060269
DESCRIPTIONUS7087409
DESCRIPTIONUS7189826
DESCRIPTIONUS7527791
DESCRIPTIONWO2005012359
DESCRIPTIONWO2005044853
DESCRIPTIONWO8906692
DESCRIPTIONWO9410202
DESCRIPTIONWO9527062
DESCRIPTIONWO9630046
DESCRIPTIONWO9704801
DESCRIPTIONWO9744453
DESCRIPTIONWO9845332
INTERNATIONAL-SEARCH-REPORTUS2006013819
INTERNATIONAL-SEARCH-REPORTUS2007166388
INTERNATIONAL-SEARCH-REPORTWO2008075330
OPPOSITIONUS2007166388
OPPOSITIONUS2011206662
OPPOSITIONWO2013135602

Non-Patent Literature (NPL) Citations New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- J. A. LEDERMANN, F. A. RAJA, "Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer", EUROPEAN JOURNAL OF CANCER, (20110901), vol. 47, no. 3, pages s104 - s115-
EXAMINATION- COHN D E ET AL, "Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 102, no. 2, doi:10.1016/J.YGYNO.2006.01.030, ISSN 0090-8258, (20060801), pages 134 - 139, (20060801), XP024921475
EXAMINATION- D. M. O'MALLEY & AL, "Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer", GYNECOLOGIC ONCOLOGY, (20110101), vol. 121, doi:10.1016/j.ygyno.2011.01.009, pages 269 - 272, XP028196737
EXAMINATION- LORTHOLARY A ET AL, "Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from GINECO", ANNALS OF ONCOLOGY, (2012), vol. 23, doi:10.1093/annonc/mdr149, pages 346 - 352, XP055687643
OPPOSITION- (20060124), URL: https://www.ema.europa.eu/en/medicines/human/EPAR/avastin#product-information-section in the section ''Product Information-
OPPOSITION- Anonymous, "AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer (NCT00976911)", Clinical Trials, Clinical Trials, URL: https://clinicaltrials.gov/archive/NCT00976911/2011_03_15, (20181130), XP055528898-
OPPOSITION- Anonymous, "AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer (NCT00976911)", ClinicalTrials.gov, (20150224), ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/history/NCT00976911?A=1&B=19&C=merged, (20200421), XP055687626-
OPPOSITION- Anonymous, "Avastin", Rote Liste 2012, Rote Liste, (20120101), page 158, XP055690834-
OPPOSITION- Anonymous, "Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer", pages 1 - 4, URL: https://clinicaltrials.gov/ct2/show/NCT00407563, (20200430), XP055690668-
OPPOSITION- Anonymous, "Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer", pages 1 - 5, URL: https://clinicaltrials.gov/ct2/show/NCT00483782, (20200430), XP055690666-
OPPOSITION- Anonymous, "GUIDELINE ON THE EVALUATION OF ANTICANCER MEDICINAL PRODUCTS IN MAN ", European Medicines Agency; COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP); CPM P/EWP/205/95/Rev J/Corr.2, (20051214), XP093210696-
OPPOSITION- Anonymous, "Highlights of prescribing informationAvastin", US BL, pages 1 - 25, US BL, (20200430), XP055690651-
OPPOSITION- Anonymous, "Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer", pages 1 - 4, URL: https://clinicaltrials.gov/ct2/show/NCT00846612, (20200430), XP055690672-
OPPOSITION- Anonymous, "revised CHMP variation assessment report", European medicines Agency, pages 1 - 67, European medicines Agency, URL: https://www.ema.europa.eu/en/documents/variation-report/avastin-h-c-582-ii-0033-epar-assessment-report-variation_en.pdf, (20200430), XP055690848-
OPPOSITION- "AURELIA: A multi-center, open-label, randomised, two-arm phase III trial of the effect on progression free survival of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer", The design of a study, (20110315), URL: www.ClinicalTrials.gov, XP055687626-
OPPOSITION- "AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer", ClinicalTrials.gov, (20150224), URL: https://clinicaltrials.gov/ct2/history/NCT00976911 ?A=1 &B=19&C=merged, (20190731), XP055687626-
OPPOSITION- "AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer (NCT00976911)", (20110315), ClinicalTrials.org, URL: https://clinicaltrials.gov/archive/NCT00976911/2011_03_15, (20170612), XP055528898-
OPPOSITION- "AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer (NCT00976911)", (20150224), ClinicalTrials.org, URL: https://clinicaltrials.qov/ct2/show/NCT00976911, XP055687626-
OPPOSITION- "AURELIA", ClinicalTrials.gov, (20110224), URL: https: / /clinicaltrials. gov/ct2/ history/ NCT0097691 1?V _19=View#Study PageTop, (20200204), XP055687626-
OPPOSITION- AURELIA STUDY PROTOCOL AS AVAILABLE, 15 March 2011 (2011-03-15), XP055528898, Retrieved from the Internet <URL:https://clinicaltrials.qov/ct2/show/NCT00976911>-
OPPOSITION- "Avastin", FDA, (20090500), URL: https://www.accessdata.fda.gov/drugsatfdadocs/label/2009/125085s0169lbl. pdf, XP055624017-
OPPOSITION- "AVASTIN HIGHLIGHTS OF PRESCRIBING INFORMATION", FDA, (20090501), pages 1 - 22, XP055624017-
OPPOSITION- BEVACIZUMAB WITH ABRAXANE IN PATIENTS WITH RECURRENT OVARIAN /PERITONEAL CANCER, 5 April 2012 (2012-04-05), XP055690668-
OPPOSITION- BURGER R A, ET AL, "Abstract No. LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study.", Journal of Clinical Oncology, (20100101), vol. 28, no. 18s, ISSN 0732-183X, pages 1 - 5, XP002639494-
OPPOSITION- "Chapter 17 Principles of Cancer Management: Chemotherapy", Cancer - Principles and practice of Oncology, (20010000), page 292, XP055688156-
OPPOSITION- D120: DECLARATION OF PROF. PFISTERER-
OPPOSITION- EMA, Assessment report on Avastin® (bevacizumab, (20111117), XP055688568-
OPPOSITION- Emea, "ICH Topic E 6 (R1) Guideline for Good Clinical Practice", European Medicines Agency, (20020701), pages 1 - 48, European Medicines Agency, URL: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r1-guideline-good-clinical-practice_en.pdf, (20220124), XP055882590-
OPPOSITION- Gerber et al., "Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies", Cancer Res., (20050000), vol. 65, no. 3, pages 671 - 680, XP002481174-
OPPOSITION- GERBER, H. P. et al., "Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies", Cancer Res, (20050000), vol. 65, no. 3, XP002481174-
OPPOSITION- G Kristensen, Et Al, "Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer", Journal of Clinical Oncology, (20160922), vol. 29, no. 18, XP055690839-
OPPOSITION- H H Sedlak, "Resistenz und Resistenzentwicklung", die Tumorerkrankungen des Menschen, de Gruyter, (20130101), pages 509 - 515, XP055690806-
OPPOSITION- J Kaern, Et Al, "A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients", European journal of gynaecological oncology, pages 383 - 389, European journal of gynaecological oncology, URL: https://www.ncbi.nlm.nih.gov/pubmed/12440808, (20200430), XP055690697-
OPPOSITION- J Petru, Et Al, "..", Praxisbuch Gynakologische Onkologie, berlin, Springer Verlag, (20110101), page 117, XP055690827-
OPPOSITION- Lucia H. Lee, Christopher L. Wu, Benjamin R. Lee, and Chi-Jen Lee, "CHAPTER 6: DECISION POINTS IN DRUG DEVELOPMENT", Lucia H. Lee, Christopher L. Wu, Benjamin R. Lee, and Chi-Jen Lee, Lee, Lee, Wu, Lee, Chen, CLINICAL TRIALS OF DRUGS AND BIOPHARMACEUTICALS, Taylor & Francis, (20060101), pages 77 - 85, ISBN 0-8493-2185-9, XP009557396-
OPPOSITION- Manfred Stapff, "A2: Die Entwicklung neuer Arzneimittel", Manfred Stapff, Manfred Stapff, Arzneimittelstudien : ein Handbuch zur Durchführung von klinischen Prüfungen speziell für Ärzte und medizinisches Assistenzpersonal; 4., unveränd. Aufl., DE, W. Zuckschwerdt Verlag, (20070101), pages 7 - 17, ISBN 978-3-88603-912-8, XP009557397-
OPPOSITION- Markman Maurie, "A phase 3 trial of bevacizumab in ovarian cancer", H1 Connect, (20131017), pages 1 - 3, H1 Connect, URL: https://archive.connect.h1.co/article/717976743/, XP093264947-
OPPOSITION- Pietzner Klaus, Schmuck Rosa Bianca, Fotopoulou Christina, Gellermann Johanna, Ismaeel Fakher, Chie Hee, Cho, Kalden Michael, Sehouli Jalid, "Long Term Combination Treatment With Bevacizumab, Pegylated Liposomal Doxorubicin and Regional Abdominal Hyperthermia in Platinum Refractory Ovarian Cancer: A Case Report and Review of the Literature", Anticancer Research, (20110801), vol. 31, no. 8, pages 2675 - 2678, XP093210688-
OPPOSITION- "progression-free survival", NCI Dictionary of Cancer Terms, URL: https://www.cancer.gov/publications/dictionaries/can ce r- terms/def/progression-free-survival-
OPPOSITION- PUJADE-LAURAINE, ERIC et al., "AURELIA: A randomized phase III trial evaluating bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer", ASCO 2012 presentation slides-
OPPOSITION- PUJADE-LAURAINE, ERIC et al., "AURELIA: A randomized phase III trial evaluating bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer", Journal of Clinical Oncology, vol. 30, no. 18, (20120000), URL: https://ascopubs.org/doi/abs/10.1200/jco.2012.30.18_suppl.lba5002, XP055687205-
OPPOSITION- RANDALL et al., "Bevacizumab toxicities and their management in ovarian cancer", Gynecol Oncol, (20100000), vol. 117, no. 3, pages 497 - 504, XP027044196-
OPPOSITION- RECIST'' NCI Dictionary of Cancer Terms, URL: https://www.cancer.gov/publications/dictionaries/can ce r- te rms/d ef/recist-
OPPOSITION- Robert J Morgan, Et Al, "Epithelial Ovarian Cancer - Clinical Practice Guidelines in Oncology", J NATL. COMPR CANC NETW, (20110101), vol. 9, no. 1, pages 82 - 113, XP055690784-
OPPOSITION- Vishai Ranpura, Et Al, "Treatment-Related Mortality With Bevacizumab in Cancer Patients A Meta-analysis", JAMA The Journal of the American Medical Association, (20110201), vol. 305, no. 5, pages 487 - 494, XP055690822-
OPPOSITION- Chen et al., "Pathology and Classification of Ovarian Tumors", Cancer Supplement, (20030000), vol. 97, no. 10, pages 2631 - 2642, XP055688175
OPPOSITION- WRIGHT JASON D. et al., "Bevacizumab Combination Therapy in Recurrent, Platinum-Refractory, Epithelial Ovarian Carcinoma", Cancer, (20060000), vol. 107, no. 1, doi:10.1002/cncr.21969, pages 83 - 89, XP002698498
OPPOSITION- Maurie Markman, "The relevant distinction between “progression” in ovarian cancer drug trials and the clinical decision to change therapy", Cancer, American cancer society , Philadelphia , PA, US, US , (20101005), vol. 117, no. 4, doi:10.1002/cncr.25459, ISSN 0008-543X, pages 660 - 661, XP071175911
OPPOSITION- MCGONIGLE KATHRYN F. et al., "Combined Weekly Topotecan and Biweekly Bevacizumab in Women with Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer", Cancer, (20110000), vol. 117, no. 16, doi:10.1002/cncr.25967, pages 3731 - 3740, XP002712134
OPPOSITION- CARTER J. et al., "Management of Large Bowel Obstruction in Advanced Ovarian Cancer with Intraluminal Stents", Gynecologic Oncology, (20020000), vol. 84, pages 176 - 179, XP055687234
OPPOSITION- SHAH, D. K. et al., "Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer", Cancer Chemother Pharmaco, (20110000), vol. 68, doi:10.1007/s00280-011-1566-3, pages 951 - 958, XP019957222
OPPOSITION- Oronsky Bryan; Ray Carolyn M.; Spira Alexander I.; Trepel Jane B.; Carter Corey A.; Cottrill Hope M., "A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer", MEDICAL ONCOLOGY, SCIENCE AND TECHNOLOGY LETTERS, NORTHWOOD, GB, GB, (20170425), vol. 34, no. 6, doi:10.1007/s12032-017-0960-z, ISSN 1357-0560, pages 1 - 7, XP036239530
OPPOSITION- McGuire, W. et al, "Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms", INTERNATIONAL JOURNAL OF GYNECOLOGY AND OBSTETRICS, NEW YORK, NY, US, US , (19900301), vol. 31, no. 3, doi:10.1016/0020-7292(90)91032-L, ISSN 0020-7292, page 298, XP023154007
OPPOSITION- VERGER, EUGENIA et al., "Can Karnofsky Performance Status be Transformed o the Eastern Cooperative Oncology Group Scoring Scale and Vice Versa?", European Journal of Cancer, (19920000), vol. 28, no. 8-9, pages 1328 - 1330, XP022643230
OPPOSITION- MARKMAN et al., "Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study", Gynecol Oncol, (20060000), vol. 101, no. 3, doi:10.1016/j.ygyno.2005.10.036, pages 436 - 440, XP024921566
OPPOSITION- MARKMAN M. et al., "Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study", Gynecologic Oncology, vol. 101, doi:10.1016/j.ygyno.2005.10.036, (20051202), pages 436 - 440, XP024921566
OPPOSITION- COHN, D. E. et al., "Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer", Gynecologic Oncolog y, (20060000), vol. 102, doi:10.1016/j.ygyno.2006.01.030, pages 134 - 139, XP024921475
OPPOSITION- Cohn, D.E. Valmadre, S. Resnick, K.E. Eaton, L.A. Copeland, L.J. Fowler, J.M., "Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer", GYNECOLOGIC ONCOLOGY., ACADEMIC PRESS, LONDON., GB, GB, (20060801), vol. 102, no. 2, doi:10.1016/j.ygyno.2006.01.030, ISSN 0090-8258, pages 134 - 139, XP005542075
OPPOSITION- NUMNUM, T. M. et al., "The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma", Gynecologic Oncology, (20060000), vol. 102, doi:10.1016/j.ygyno.2006.05.018, pages 425 - 428, XP024921964
OPPOSITION- SIMPKINS et al., "Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening", Gynecol Oncol, (20070000), vol. 107, no. 1, doi:10.1016/j.ygyno.2007.06.004, pages 118 - 123, XP022274926
OPPOSITION- Simpkins, F. Belinson, J.L. Rose, P.G., "Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening", GYNECOLOGIC ONCOLOGY., ACADEMIC PRESS, LONDON., GB, GB, (20070927), vol. 107, no. 1, doi:10.1016/j.ygyno.2007.06.004, ISSN 0090-8258, pages 118 - 123, XP022274926
OPPOSITION- HURT et al., "Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer", Gynecol Oncol, (20090000), vol. 115, no. 3, doi:10.1016/j.ygyno.2009.08.032, pages 396 - 400, XP026733152
OPPOSITION- HURT et al., "Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer", Gynecol Oncol., (20091200), vol. 115, no. 3, pages 396 - 400, XP026733152
OPPOSITION- HURT, J. D. et al., "Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer", Gynecologic Oncology, (20090000), vol. 115, doi:10.1016/j.ygyno.2009.08.032, pages 396 - 400, XP026733152
OPPOSITION- HURT, J.D. et al., "Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer", Gynecologic Oncolog y, (20090000), vol. 115, no. 3, doi:10.1016/j.ygyno.2009.08.032, pages 396 - 400, XP026733152
OPPOSITION- HURT J.D. et al., "Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer", Gynecologic Oncology, vol. 115, doi:10.1016/j.ygyno.2009.08.032, (20091004), pages 396 - 400, XP026733152
OPPOSITION- D L Richardson,, F.J. Backes, J.D. Hurt, L.G. Seamon, L.J. Copeland, J.M. Fowler, D.E. Cohn, D.M. O'malley, "Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?", GYNECOLOGIC ONCOLOGY., ACADEMIC PRESS, LONDON., GB, GB, (20100101), vol. 118, doi:10.1016/j.ygyno.2010.01.011, ISSN 0090-8258, pages 47 - 51, XP055687819
OPPOSITION- RICHARDSON, D. L. et al., "Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?", Gynecologic Oncology, (20100000), vol. 118, pages 47 - 51, XP055687819
OPPOSITION- TANYI et al., "Clinical predictors of bevacizumab-associated gastrointestinal perforation", Gynecol Oncol, (20110000), vol. 120, no. 3, doi:10.1016/j.ygyno.2010.11.009, pages 464 - 469, XP028364121
OPPOSITION- Robert A. Burger;, "Overview of anti-angiogenic agents in development for ovarian cancer", GYNECOLOGIC ONCOLOGY., ACADEMIC PRESS, LONDON., GB, GB, vol. 121, no. 1, doi:10.1016/j.ygyno.2010.11.035, ISSN 0090-8258, pages 230 - 238, XP028164685
OPPOSITION- David M. O'Malley; Debra L. Richardson; Patrick S. Rheaume; Ritu Salani; Eric L. Eisenhauer; Georgia A. McCann; Jeffrey M. Fowler; Larry J. Copeland; David E. Cohn; Floor J. Backes;, "Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer", GYNECOLOGIC ONCOLOGY., ACADEMIC PRESS, LONDON., GB, GB, vol. 121, no. 2, doi:10.1016/j.ygyno.2011.01.009, ISSN 0090-8258, pages 269 - 272, XP028196737
OPPOSITION- O'MALLEY, DAVID M. et al., "Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer", Gynecologic Oncology, (20110000), vol. 121, no. 2, doi:10.1016/j.ygyno.2011.01.009, pages 269 - 272, XP028196737
OPPOSITION- O'MALLEY, D. et al., "Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer", Gynecologic Oncology, (20110000), vol. 121, doi:10.1016/j.ygyno.2011.01.009, pages 269 - 272, XP028196737
OPPOSITION- O'MALLEY D.M. et al., "Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer", Gynecologic Oncology, vol. 121, doi:10.1016/j.ygyno.2011.01.009, (20110218), pages 269 - 272, XP028196737
OPPOSITION- O'MALLEY et al., "Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer", Gynecologic Oncology, (20110000), vol. 121, pages 269 - 272, XP028196737
OPPOSITION- O'MALLEY et al., "Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer", Gynecol Oncol, (20110000), vol. 121, no. 2, doi:10.1016/j.ygyno.2011.01.009, pages 269 - 272, XP028196737
OPPOSITION- O'MALLEY et al., "Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer", Gynecol Oncol., (20110501), vol. 121, no. 2, pages 269 - 272, XP028196737
OPPOSITION- Robert L. Coleman et al, "A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study", GYNECOLOGIC ONCOLOGY., ACADEMIC PRESS, LONDON., GB, GB , vol. 122, no. 1, doi:10.1016/j.ygyno.2011.03.036, ISSN 0090-8258, pages 111 - 115, XP028095261
OPPOSITION- T D Tillmanns, Et Al, "Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.", Gynecologic Oncology, (20130201), pages 221 - 228, XP055690712
OPPOSITION- Alvarez Ronald D.; Matulonis Ursula A.; Herzog Thomas J.; Coleman Robert L.; Monk Bradley J.; Markman Maurie, "Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer", GYNECOLOGIC ONCOLOGY., ACADEMIC PRESS, LONDON., GB, GB, (20160408), vol. 141, no. 3, doi:10.1016/j.ygyno.2016.03.005, ISSN 0090-8258, pages 405 - 409, XP029544249
OPPOSITION- HU, L. et al., "Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer", American Journal of Pathology, (20020000), vol. 161, no. 5, pages 1917 - 1924, XP055688150
OPPOSITION- Jonathan A. Ledermann, Fharat A. Raja, "Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer", European Journal of Cancer, Elsevier, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, (20110901), vol. 47, doi:10.1016/S0959-8049(11)70154-X, ISSN 0959-8049, pages S104 - S115, XP055528877
OPPOSITION- Jonathan A. Ledermann, Fharat A. Raja, "Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer", European Journal of Cancer, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20110901), vol. 47, doi:10.1016/S0959-8049(11)70154-X, ISSN 0959-8049, pages S104 - S115, XP055528877
OPPOSITION- LEDERMANN et al., "Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer", Eur J Cancer., (20110900), vol. 3, pages 5104 - 5115, XP055528877
OPPOSITION- LEDERMANN et al., "Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer", European Journal of Cancer, (20110000), vol. 47, no. 3, pages S104 - S115, XP055528877
OPPOSITION- LEDERMANN J.A. et al., "Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer", (20110900), vol. 47, doi:10.1016/S0959-8049(11)70154-X, pages S104 - S115, XP055528877
OPPOSITION- LEDERMANN, J. A. et al., "Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer", European Journal of Cancer, (20110000), vol. 47, no. 3, pages S104 - S115, XP055528877
OPPOSITION- LEDERMANN, JONATHAN A et al., "Clinical trials and decision- making strategies for optimal treatment of relapsed ovarian cancer", European Journal of Cancer, (20110000), vol. 47, no. 3, doi:10.1016/S0959-8049(11)70154-X, pages S104 - S115, XP055528877
OPPOSITION- BAIRD, RD et al., "Weekly paclitaxel in the treatment of recurrent ovarian cancer", Nature Reviews Clinical Oncology, (20100000), vol. 7, no. 10, pages 575 - 582, XP055687126
OPPOSITION- BURGER et al., "Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer", The New England Journal of Medicine, (20110000), vol. 365, pages 2473 - 2484, XP055688245
OPPOSITION- J.J. Biagi, Et Al, "A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study", ANNALS OF ONCOLOGY., KLUWER, DORDRECHT., NL, NL, (20110201), vol. 22, no. 2, doi:10.1093/annonc/mdq357, ISSN 0923-7534, pages 335 - 340, XP055690657
OPPOSITION- LEDERMANN et al., "Optimal treatment for relapsing ovarian cancer", Annals of Oncology, (20100000), vol. 21, pages vii218 - vii222, XP055688573
OPPOSITION- LORTHOLARY et al., "Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistance ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO", Ann Oncol., (20120200), vol. 23, no. 2, pages 346 - 352, XP055687643
OPPOSITION- BURGER, R. A., "Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer", Annals of Oncology, (20110000), vol. 22, no. 8, pages viii65 - viii68, XP055688153
OPPOSITION- Sebastiano Buti, Et Al, "Dose-finding Trial of a Combined Regsimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study", Journal of Immunotherapy, Lippincott Williams & Wilkins, US, US, (20100901), vol. 33, no. 7, doi:10.1097/CJI.0b013e3181eb8289, ISSN 1524-9557, pages 735 - 741, XP055690726
OPPOSITION- Sato Shinya; Itamochi Hiroaki, "Bevacizumab and ovarian cancer.", Current opinion in obstetrics & gynecology, Current Science, UK, UK, (20120201), vol. 24, no. 1, doi:10.1097/GCO.0b013e32834daeed, ISSN 1473-656X, pages 8 - 13, XP008162806
OPPOSITION- TEOH, D., "Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer", Int J Gynecol Cancer, (20120301), vol. 22, pages 348 - 359, XP055687823
OPPOSITION- TEOH, D. et al., "Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer", Int J Gynecol Cancer, (20120301), vol. 22, pages 348 - 359, XP055687823
OPPOSITION- Mauri Markman, Et Al, "Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.", Journal of Clinical Oncology, (19910301), vol. 9, no. 3, pages 389 - 393, XP055690646
OPPOSITION- Thigpen J T. et al, "Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.", Journal of Clinical Oncology, Grune & Stratton, (19940901), vol. 12, no. 9, doi:10.1200/JCO.1994.12.9.1748, ISSN 0732-183X, pages 1748 - 1753, XP093257246
OPPOSITION- BURGER et al., "Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study", J Clin Oncol, (20070000), vol. 25, no. 33, doi:10.1200/JCO.2007.11.5345, pages 5165 - 5171, XP055545111
OPPOSITION- BURGER et al., "Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study", Journal of Clinical Oncology, (20070000), vol. 25, pages 5165 - 5171, XP055545111
OPPOSITION- Robert A. Burger, Michael W. Sill, Bradley J. Monk, Benjamin E. Greer, Joel I. Sorosky, "Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study", Journal of Clinical Oncology, (20071120), vol. 25, no. 33, doi:10.1200/JCO.2007.11.5345, ISSN 0732-183X, pages 5165 - 5171, XP055545111
OPPOSITION- CANNISTRA et al., "Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer", Journal of Clinical Oncology, (20070000), vol. 25, pages 5180 - 5186, XP055377324
OPPOSITION- Cannistra et al., "Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer", JOURNAL OF CLINICAL ONCOLOGY, (20071120), pages 5180 - 5186, XP055377324
OPPOSITION- Stephen A. Cannistra et al, "Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer", Journal of Clinical Oncology, (20071120), vol. 25, no. 33, doi:10.1200/JCO.2007.12.0782, ISSN 0732-183X, pages 5180 - 5186, XP055377324
OPPOSITION- Stephen A. Cannistra, Ursula A. Matulonis, Richard T. Penson, Julie Hambleton, Jakob Dupont, Howard Mackey, Jeffrey Douglas, Robert A. Burger, Deborah Armstrong, Robert Wenham, William Mcguire, "Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer", Journal of Clinical Oncology, (20071120), vol. 25, no. 33, doi:10.1200/JCO.2007.12.0782, ISSN 0732-183X, pages 5180 - 5186, XP055377324
OPPOSITION- BURGER, ROBERT A et al., "Experience With Bevacizumab in the Management of Epithelial Ovarian Cancer", Journal of Clinical Oncology, (20070000), vol. 25, no. 20, doi:10.1200/JCO.2007.12.1509, pages 2902 - 2908, XP008162807
OPPOSITION- Stanley B. Kaye, "Bevacizumab for the Treatment of Epithelial Ovarian Cancer: Will This Be Its Finest Hour?", Journal of Clinical Oncology, (20071120), vol. 25, no. 33, doi:10.1200/JCO.2007.13.6150, ISSN 0732-183X, pages 5150 - 5152, XP055690831
OPPOSITION- Teneriello Michael G. et al, "Phase II Evaluation of Nanoparticle Albumin-Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer", Journal of Clinical Oncology, Grune & Stratton, (20090320), vol. 27, no. 9, doi:10.1200/JCO.2008.18.9548, ISSN 0732-183X, pages 1426 - 1431, XP093008904
OPPOSITION- T D Tillmans, M P Lowe, L S Schwartzberg, M S Walker, E J Stepanski, "A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma", Journal of Clinical Oncology, doi:10.1200/jco.2010.28.15_suppl.5009, (20160922), Journal of Clinical Oncology, (20200422), XP055688145
OPPOSITION- TILLMANNS et al., "A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma", Journal of Clinical Oncology, (20100000), vol. 28, XP055688145
OPPOSITION- TILLMANNS, T. D. et al., "A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma", Journal of Clinical Oncology, (20100000), vol. 28, no. 15, pages 5009 - 5009, XP055688145
OPPOSITION- TILLMANNS, T. D. et al., "A phase II study of bevacizumab with nab- paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma", Journal of Clinical Oncology, (20100520), vol. 28, no. 15, XP055688145
OPPOSITION- PUJADE-LAURAINE, E. et al., "Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial", Journal of Clinical Oncology, (20140000), vol. 32, no. 13, pages 1302 - 1308, XP055687749
OPPOSITION- PETRELLI et al., "Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxef", Expert Opinion on Pharmacotherapy, vol. 11, no. 8, doi:10.1517/14656561003796562, (20100506), pages 1413 - 1432, XP055376216
OPPOSITION- Han Ernest S; Monk Bradley J, "Bevacizumab in the treatment of ovarian cancer.", EXPERT REVIEW OF ANTICANCER THERAPY, FUTURE DRUGS LTD., UK, UK, (20071001), vol. 7, no. 10, doi:10.1586/14737140.7.10.1339, ISSN 1744-8328, pages 1339 - 1345, XP009148910
OPPOSITION- PAZDUR, R., "Endpoints for assessing drug activity in clinical trials", The Oncologist, (20080000), vol. 13, pages 19 - 21, XP055687828
OPPOSITION- ESKANDER, RAMEZ N et al., "Bevacizumab in the treatment of ovarian cancer", Biologics: Targets and Therapy, (20110000), vol. 5, pages 1 - 5, XP055687182
OPPOSITION- NAUMANN, R. W. et al., "Management strategies for recurrent platinum- resistant ovarian cancer", Drugs, (20110000), vol. 71, no. 11, doi:10.2165/11591720-000000000-00000, pages 1397 - 412, XP009165133
OPPOSITION- Jain et al., "Weekly paclitaxel in ovarian cancer- the latest success story", Current Oncology, (20110000), vol. 18, no. 1, pages 16 - 17, XP055501548
OPPOSITION- UMSCHEID, C. A. et al., "Key concepts of clinical trials: a narrative review", NIH Public Access Author Manuscript, (20110000), vol. 123, no. 5, pages 1 - 16, XP055688166

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents